UBS Group’s BIND Therapeutics BIND Stock Holding History
Bought
Maintained
Sold
UBS Group's BIND Position: Q3 2016 in Review
UBS Group sold out of BIND Therapeutics (BIND) in Q3 2016, closing a stake of 37,601 shares — an estimated $15K sold.
UBS Group first reported a position in BIND in Q4 2014 and held it in 7 quarters. The position peaked at $39K in Q2 2015. 0 funds tracked by Wall St. Rank hold BIND as of Q3 2016.
- UBS Group reported no remaining BIND Therapeutics position as of Q3 2016 after selling out during the quarter.
- UBS Group sold 37,601 BIND Therapeutics shares in Q3 2016, an estimated $15K.
- UBS Group first reported a position in BIND Therapeutics in Q4 2014 and held it in 7 quarters.
- UBS Group's BIND Therapeutics position peaked at $39K in Q2 2015.
- 0 funds tracked by Wall St. Rank held BIND Therapeutics as of Q3 2016.
Based on UBS Group's 13F filing for Q3 2016, filed 14 Nov 2016.